AG真人官方

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.听as Senior Vice President, Regulatory Strategy

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance鈥檚 pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.

For more than 15 years, Dr. Theoret held various roles in the United States Food and Drug Administration (FDA) within the Oncology Center of Excellence (OCE) as well as the Center for Drug Evaluation and Research (CDER). For the past five years, he served as Deputy Center Director, OCE and Acting Supervisory Associate Director in the Office of Oncologic Diseases (OOD), CDER. Dr. Theoret led regulatory reviews of drugs and biologics for hematological malignancies and solid tumors, including melanoma and tissue agnostic development. He contributed to the approval of numerous oncology applications within this role and concurrent or former leadership roles within OCE and CDER. He is also a past recipient of the FDA Scientific Achievement Team Award for Excellence in Review Science.

Prior to his tenure at the U.S. FDA, Dr. Theoret spent three years conducting adoptive cellular therapy trials for patients with melanoma and other solid tumors and translational science research at the National Cancer Institute as a clinical fellow in Hematology/Oncology. Previously he served as Intern and Resident in Internal Medicine, and Clinical Fellow at Harvard Medical School, Beth Israel Deaconess Medical Center.

鈥淲e are excited to welcome Marc to Iovance as we further our mission of developing and delivering novel therapies to patients with solid tumors,鈥� said Dr. Puri. 鈥淢arc鈥檚 extensive regulatory expertise and leadership experience within the FDA鈥檚 Oncology Center of Excellence will be a significant contribution as we advance our pipeline and regulatory strategies across multiple solid tumor cancers.鈥�

About听Iovance Biotherapeutics, Inc.听

, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system鈥檚 ability to recognize and destroy diverse cancer cells in each patient. The has demonstrated promising clinical data across multiple solid tumors. Iovance鈥檚 Amtagvi^庐 is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit .

Amtagvi ^庐听and its accompanying design marks, Proleukin^庐, Iovance^庐, and IovanceCares鈩⑻齛re trademarks and registered trademarks of听Iovance Biotherapeutics, Inc.听or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are 鈥渇orward-looking statements鈥� of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渦s,鈥� or 鈥渙ur鈥�) within the meaning of the Private Securities Litigation Reform Act of 1995 (the 鈥淧SLRA鈥�). Without limiting the foregoing, we may, in some cases, use terms such as 鈥減redicts,鈥� 鈥渂elieves,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渆stimates,鈥� 鈥渁nticipates,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渋ntends,鈥� 鈥渇orecast,鈥� 鈥済uidance,鈥� 鈥渙utlook,鈥� 鈥渕ay,鈥� 鈥渃an,鈥� 鈥渃ould,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management鈥檚 experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (鈥淔DA鈥�) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (鈥淓MA鈥�) approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates.

CONTACTS听

Investors
[email protected]
650-260-7120听ext. 150

Media
[email protected]听
650-260-7120听ext. 150